Page 16 - Kirin Holdings Case Study

Development of four major modalities

Diagram 4; Source: Kirin Report 2018 (4)

In the Kyowa Hakko Kirin pharmaceuticals and bio-

chemicals business steady progress had been made with

development of its global strategic products, KRN23

(Burosumab) and KW-0761 (Mogamulizumab). In February

2018 the European Medicines Agency (EMA) granted
Conditional Marketing Authorisation to KRN23 whilst in April

2018 it had obtained FDA marketing approval. Isozaki also

planned to launch KRN23 in both the U.S. and Europe within
the year.

In 2019 the Kirin Group formulated its Long-Term

Management Vision “Kirin Group Vision 2027” (“KV2027”)

and the “Kirin Group 2019-2021 Medium-Term Business
Plan” (“2019 MTBP”). This first three-year plan for realizing

KV2027 was accompanied by a revised management

philosophy with a new corporate slogan aimed at clarifying
its commitment to contributing to society through its

business activities.

In order to meet its stakeholders’ expectations, the Kirin

Group would continue to commit to the “customer-oriented”
and “quality-oriented” tradition which it had embraced since